Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Viridian Therapeutics, retaining the price target of $46.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rami Katkhuda has given his Buy rating due to a combination of factors that position Viridian Therapeutics favorably in the market. The company has secured a significant royalty financing agreement with DRI Healthcare Acquisition LP, providing up to $300 million in nondilutive capital. This includes $55 million upfront and $115 million tied to near-term milestones, which is expected to fully fund the anticipated commercial launches of their assets in Thyroid Eye Disease (TED). The structured royalty payments are advantageous, with no royalties owed on annual net sales exceeding $2 billion, indicating a potential for substantial revenue growth.
Additionally, Viridian has announced updated timelines for its TED treatments, with a Biologics License Application for veligrotug expected imminently and a potential mid-2026 commercial launch. The FDA has granted veligrotug Breakthrough Therapy Designation due to its rapid and robust response in both active and chronic TED patients. The pivotal topline data for VRDN-003 is expected in 2026, and the positive THRIVE results help mitigate risks associated with the REVEAL program. These developments highlight the clinical differentiation and market potential of Viridian’s treatments, supporting the Buy rating.
In another report released on October 17, Jefferies also maintained a Buy rating on the stock with a $44.00 price target.